Laura Litwin

Laura Litwin

Articles by Laura Litwin

Laura LitwinNon-Small Cell Lung Cancer | February 27, 2025
Clinicians hypothesize that the genetic mutation, known as RUFY1-RET fusion, caused resistance to lorlatinib.
Read More
Laura LitwinLung Cancer | February 18, 2025
A multicenter study that included 21,062 patients who were seen from 2009-2021 in South Korea provided key insights.
Robert E. Merritt, MD, MBA, FACSNon-Small Cell Lung Cancer | February 7, 2025
Dr. Merritt shares new thoracic surgery research insights for patient selection in sublobar resection for early-stage NSCLC.
Robert E. Merritt, MD, MBA, FACSNon-Small Cell Lung Cancer | February 28, 2025
Robert E. Merritt, MD, MBA, FACS, shares insights on his systematic review of sublobar resection and lobectomy.
Laura LitwinEGFR+ NSCLC | January 22, 2025
The ORR of the external control group was 3%, while it was 36.8% in those who received amivantamab for NSCLC.
Laura LitwinNon-Small Cell Lung Cancer | January 17, 2025
Learn how sublobar resection showed "comparable oncologic outcomes and complication rates" as lobectomy per a recent review.
Laura LitwinEGFR+ NSCLC | January 7, 2025
For patients with NSCLC and EGFR mutations, amivantamab plus carboplatin-pemetrexed shows OS benefits versus chemo alone.
Laura LitwinLung Cancer | December 24, 2024
A new study illustrated the importance of exercise for patients with lung cancer who experience cancer-related fatigue.
Laura LitwinNon-Small Cell Lung Cancer | December 20, 2024
Home-based exercise programs after lung cancer resection do not improve physical function in patients with NSCLC.
Laura LitwinNon-Small Cell Lung Cancer | December 20, 2024
Implementing pretreatment frailty assessments into clinical workflows may help identify patients at risk of poor outcomes.
Laura LitwinLung Cancer | December 20, 2024
Researchers evaluated if commercially available AI software was capable of detecting lung cancer in chest radiographs.
Laura LitwinLung Cancer | December 16, 2024
Researchers say the conventional criteria may underestimate the condition in Asian patients with lung cancer.
Laura LitwinImmunotherapy in NSCLC | December 11, 2024
The new study is working to identify additional therapeutic combinations targeted towards patients with NSCLC and low PD-L1.
Laura LitwinNon-Small Cell Lung Cancer | December 10, 2024
Veterans with high socioeconomic deprivation experience suboptimal access to pre- and postoperative care for NSCLC.
Laura LitwinLung Cancer | December 9, 2024
The burden of disease is expected to increase to 4.62 million new cases and 3.55 million deaths by 2050.
Laura LitwinImmunotherapy in NSCLC | December 6, 2024
Patients with NSCLC, treated with an immunotherapy regimen, have a higher risk of pneumonitis with decreased lung volume.
Laura LitwinImmunotherapy in NSCLC | December 4, 2024
An analysis of the CCTG BR.34 trial showed that bone metastasis correlated with worse outcomes in patients with NSCLC.
Laura LitwinLung Cancer | December 3, 2024
A novel dietary pattern was linked to lower lung cancer incidence in people who were former smokers
Laura LitwinNon-Small Cell Lung Cancer | December 2, 2024
The study explored the relationship between sociodemographic disparities and access to minimally-invasive surgery for NSCLC.
Laura LitwinSmall Cell Lung Cancer | November 21, 2024
For patients with Schlafen 11-positive ES-SCLC, atezolizumab plus talazoparib showed an PFS improvement after chemotherapy.